

PARTIAL RESPONSE TO ACCC INFORMATION REQUEST DATED 16 DECEMBER 2021¹

Red is not to be shared with the public

1. Rationale / Industry Background Information

Generic products

- 1.1 ***Explain Celgene's strategy in relation to actions taken in response to the proposed launch of any generic products that will compete with Celgene's originating products, either generally in relation to any generic products or in relation to Juno/Natco's products specifically, and either in Australia or in locations including Australia.***

Celgene's response to this question is limited to Australia, as that is the jurisdiction where authorisation is sought.

[Redacted]

- 1.2 **For each Celgene Product and indication provide the following:**

- (a) ***annual sales volumes in Australia for the past 3 financial years;***
- (b) ***projected sales volumes in Australia for the first 3 financial years under the Agreement;***
- (c) ***total revenue in Australia for the past 3 financial years; and***
- (d) ***projected revenue in Australia for the first 3 financial years under the Agreement.***

Please provide Documents to support the response to this question.

In relation to 1.2(a) and 1.2(c), Celgene notes that some limited historical sales and volumes for Revlimid® and Pomalyst® are available on the websites for the PBS and Medicare².

The information provided in Tables 1-3 below is confidential to Celgene.

[Redacted]

¹ All capitalised terms used in this response have the definition given to them in the ACCC Information Request or the ACCC authorisation application dated 3 December 2021 made by Juno Pharmaceuticals Pty Ltd, Natco Pharma Ltd, and Celgene (**Authorisation Application**) unless otherwise indicated.

² <https://www.pbs.gov.au/info/statistics/expenditure-prescriptions/pbs-expenditure-and-prescriptions-report-30-june-2021>; <https://www.pbs.gov.au/statistics/hsd-expenditure-reports/highly-specialised-drugs-program-national-expenditure-report-1-jul-2018-to-30-jun-2020.XLSX>.